Mandate

Vinge advises Main Capital in connection with the sale of Alfa eCare

Vinge has advised Main Capital in connection with the sale of Alfa eCare Holding AB and its subsidiaries (“Alfa eCare”) to SDB Groep B.V. (“SDB”)

Alfa eCare is a leading provider of digital healthcare, welfare and childcare software in the Nordics. Headquartered in Sweden with offices in Finland and Denmark, Alfa eCare employs approximately 120 people and serves over 1,300 clients across public and private sectors. SDB is a market leading healthcare and childcare software player in the Netherlands, serving elderly care, disabled care, mental health, rehabilitation, youth care, childcare, and independent treatment centers (ITCs).

SDB and Alfa eCare are joining forces to create a leading position in the European Healthcare and Welfare market. The combination establishes a unique player, which offers a comprehensive modular suite of solutions for primary and secondary processes of healthcare and welfare organizations across Europe.

Vinge’s team consisted primarily of Filip Öhrner, Jonatan Stentorp, Ian Linde (M&A), Felix Möller, Sofia Haggren (Banking & Finance), Martin Boström, Siri Blomberg (Commercial Agreements and IT & GDPR), Alice Göransson, Louisa Fagarasan (Employment), Felizia Wiker (IP), Caroline Löv och Jasmina Skandrani (Transaction Support).

Related

Vinge has advised Eleda in connection with Eleda Norge AS’s acquisition of Nettpartner Bane AS

Vinge, together with Advokatfirmaet Thommessen, has advised Eleda in connection with Eleda Norge AS’s acquisition of Nettpartner Bane AS from Å Energi owned Nettpartner AS.
January 19, 2026

Vinge advises KEYTO Group in connection with the acquisition of Smartify

KEYTO Group continues its growth journey by strengthening its offering in Sweden as Smartify Sverige AB joins KEYTO Group.
January 19, 2026

Vinge has advised Orexo in connection with the divestment of the US rights to Zubsolv

Vinge has advised Orexo in relation to Swedish law in connection with the divestment of the US rights to Zubsolv to Dexcel Pharma USA.
January 14, 2026